AMGN
$361.13
Amgen Inc.
Recent News
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
Amgen Inc. and GSK plc are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. This move will augment the total number of discounted prescription medications available on the platform to 54, from five different pharmaceutical companies, according to a report by FOX Business on Friday. Amgen will offer an 80% discount on Amjevita, a medication used for rheumatoid arthritis, psoriasis, and ulcerative colitis
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Amgen (AMGN) closed at $361.13 in the latest trading session, marking a -1.4% move from the prior day.
Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
Amgen Inc. (NASDAQ:AMGN) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Amgen Inc. (NASDAQ:AMGN) is also a staple in the 13F portfolio of Fisher Asset Management. The fund has held a small position in the company since early 2010. This position remained relatively stable through the decade and half since 2010. […]
How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
Analysts have lifted their fair value estimate for Amgen from US$327.74 to US$350.03, a move of about 6.8% that puts fresh attention on what is already a closely watched large cap biotech name. This shift is being framed around a mix of confidence in current execution and key pipeline assets like obesity candidate MariTide, set against ongoing debate about product risks and how much long term earnings power to factor into models. As you read on, you will see how to track these evolving views...
Grail CEO Bob Ragusa to retire
Josh Ofman, company president, will step into the top job. Guggenheim Securities analysts said the leadership change “has been in development for some time and is unrelated to the NHS trial readout."